- Home
- MTG vs BBIO Comparison
MTG vs BBIO Comparison
Compare MTG & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTG
- BBIO
- Stock Information
- Founded
- MTG 1957
- BBIO 2015
- Country
- MTG United States
- BBIO United States
- Employees
- MTG N/A
- BBIO N/A
- Industry
- MTG Property-Casualty Insurers
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MTG Finance
- BBIO Health Care
- Exchange
- MTG Nasdaq
- BBIO Nasdaq
- Market Cap
- MTG 6.0B
- BBIO 6.3B
- IPO Year
- MTG 1991
- BBIO 2019
- Fundamental
- Price
- MTG $23.07
- BBIO $31.19
- Analyst Decision
- MTG Hold
- BBIO Strong Buy
- Analyst Count
- MTG 8
- BBIO 12
- Target Price
- MTG $26.75
- BBIO $52.64
- AVG Volume (30 Days)
- MTG 3.5M
- BBIO 2.6M
- Earning Date
- MTG 04-30-2025
- BBIO 05-01-2025
- Dividend Yield
- MTG 2.13%
- BBIO N/A
- EPS Growth
- MTG 16.23
- BBIO N/A
- EPS
- MTG 2.89
- BBIO N/A
- Revenue
- MTG $1,207,731,000.00
- BBIO $221,902,000.00
- Revenue This Year
- MTG $3.42
- BBIO $12.42
- Revenue Next Year
- MTG $2.72
- BBIO $123.19
- P/E Ratio
- MTG $8.47
- BBIO N/A
- Revenue Growth
- MTG 4.56
- BBIO 2285.27
- 52 Week Low
- MTG $19.26
- BBIO $21.62
- 52 Week High
- MTG $26.56
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- MTG 42.65
- BBIO 44.04
- Support Level
- MTG $24.19
- BBIO $32.83
- Resistance Level
- MTG $25.57
- BBIO $34.86
- Average True Range (ATR)
- MTG 0.53
- BBIO 1.59
- MACD
- MTG 0.05
- BBIO -0.21
- Stochastic Oscillator
- MTG 14.12
- BBIO 16.85
About MTG MGIC Investment Corporation
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection accounts for close to majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia and New York.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.